Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.
Nat Commun · 2022
Last updated 2026-05-28Researchers studied how four different GLP-1 drugs (including exendin-4) interact with the GLP-1 receptor and activate G proteins. They found that faster, more temporary interactions between the drugs and the receptor led to quicker activation of G proteins, which may explain why some drugs work better than others.
AI summary of the abstract below.
| Journal | Nat Commun, 2022 |
|---|---|
| Citations | 63 |
| Relative citation ratio | 5.53 |
| NIH percentile | 93 |
| Molecules | — |
Abstract
The glucagon-like peptide-1 receptor (GLP-1R) has broad physiological roles and is a validated target for treatment of metabolic disorders. Despite recent advances in GLP-1R structure elucidation, detailed mechanistic understanding of how different peptides generate profound differences in G protein-mediated signalling is still lacking. Here we combine cryo-electron microscopy, molecular dynamics simulations, receptor mutagenesis and pharmacological assays, to interrogate the mechanism and consequences of GLP-1R binding to four peptide agonists; glucagon-like peptide-1, oxyntomodulin, exendin-4 and exendin-P5. These data reveal that distinctions in peptide N-terminal interactions and dynamics with the GLP-1R transmembrane domain are reciprocally associated with differences in the allosteric coupling to G proteins. In particular, transient interactions with residues at the base of the binding cavity correlate with enhanced kinetics for G protein activation, providing a rationale for differences in G protein-mediated signalling efficacy from distinct agonists.
Verbatim abstract via PubMed 35013280 ↗